{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:56:28Z","timestamp":1789095388076,"version":"build-2803163510"},"reference-count":236,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.drudis.2025.104450","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T23:41:15Z","timestamp":1755128475000},"page":"104450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Discovery of novel anti-fibrotics through phenotypic screening"],"prefix":"10.1016","volume":"30","author":[{"given":"Alice R.","family":"Lapthorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie L.","family":"Harding-Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran M.","family":"Feltham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus M.","family":"Ilg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4856-285X","authenticated-orcid":false,"given":"Selim","family":"Cellek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104450_b0005","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41573-025-01190-9","article-title":"Publisher correction: Fibrosis: cross-organ biology and pathways to development of innovative drugs","volume":"24","author":"Rieder","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2025.104450_b0010","first-page":"15","article-title":"Fibrogenesis and fibrolysis in the liver","volume":"79","author":"Herbst","year":"1995","journal-title":"Verh Dtsch Ges Pathol"},{"key":"10.1016\/j.drudis.2025.104450_b0015","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1172\/JCI93561","article-title":"Mechanosensing and fibrosis","volume":"128","author":"Tschumperlin","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2025.104450_b0020","doi-asserted-by":"crossref","DOI":"10.70322\/fibrosis.2024.10005","article-title":"A review of the current landscape of anti-fibrotic medicines","volume":"2","author":"Lapthorn","year":"2024","journal-title":"Fibrosis"},{"key":"10.1016\/j.drudis.2025.104450_b0025","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nri1412","article-title":"Fibrotic disease and the TH1\/TH2 paradigm","volume":"4","author":"Wynn","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2025.104450_b0030","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s41030-023-00226-y","article-title":"Post-COVID-19 pulmonary fibrosis: facts\u2014challenges and futures: a narrative review","volume":"9","author":"Duong-Quy","year":"2023","journal-title":"Pulm Ther"},{"key":"10.1016\/j.drudis.2025.104450_b0035","article-title":"Possible mechanisms of SARS-CoV-2-associated myocardial fibrosis: reflections in the post-pandemic era","volume":"15","author":"Wang","year":"2024","journal-title":"Front Microbiol"},{"key":"10.1016\/j.drudis.2025.104450_b0040","unstructured":"Research and Markets. Liver fibrosis & NASH\/MASH drugs market report 2025\u20132035: regulatory challenges and market barriers in NASH\/MASH drug approval. https:\/\/www.globenewswire.com\/news-release\/2025\/04\/09\/3058224\/28124\/en\/Liver-Fibrosis-NASH-MASH-Drugs-Market-Report-2025-2035-Regulatory-Challenges-and-Market-Barriers-in-NASH-MASH-Drug-Approval; Date of access 20th August 2025."},{"key":"10.1016\/j.drudis.2025.104450_b0045","unstructured":"Persistence Market Research. Pulmonary fibrosis treatment market: global industry analysis, size, share, growth, trends, and forecast, 2024\u20132033. https:\/\/www.giiresearch.com\/report\/pmrs1500815-pulmonary-fibrosis-treatment-market-by-product.html; Date of access 20th August 2025."},{"key":"10.1016\/j.drudis.2025.104450_b0050","unstructured":"MarketResearch.biz. Kidney fibrosis treatment market by treatment type, by diagnosis, by end-user, by region and companies, trends and forecast 2024\u20132033. https:\/\/marketresearch.biz\/report\/kidney-fibrosis-treatment-market\/; Date of access 20th August 2025."},{"key":"10.1016\/j.drudis.2025.104450_b0055","unstructured":"Verified Market Research. Global myocardial fibrosis market size by product type, by application, by geographic scope and forecast. https:\/\/www.verifiedmarketresearch.com\/product\/myocardial-fibrosis-market\/; Date of access 20th August 2025."},{"key":"10.1016\/j.drudis.2025.104450_b0060","unstructured":"Zion Market Research. Hypertrophic and keloid scar treatment market. https:\/\/www.zionmarketresearch.com\/report\/hypertrophic-and-keloid-scar-treatment-market. Date of access 20th August 2025."},{"key":"10.1016\/j.drudis.2025.104450_b0065","unstructured":"Grand View Research. Crohn\u2019s disease therapeutics market trends. https:\/\/www.grandviewresearch.com\/industry-analysis\/crohns-disease-therapeutics-market. Date of access 20th August 2025."},{"key":"10.1016\/j.drudis.2025.104450_b0070","unstructured":"Research Nester. Adhesion barrier market size & share by product. https:\/\/www.researchnester.com\/reports\/adhesion-barrier-market\/4535; Date of access 20th August 2025."},{"key":"10.1016\/j.drudis.2025.104450_b0075","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrd4609","article-title":"An analysis of the attrition of drug candidates from four major pharmaceutical companies","volume":"14","author":"Waring","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2025.104450_b0080","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1080\/13543784.2020.1839888","article-title":"The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success","volume":"29","author":"Drenth","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.drudis.2025.104450_b0085","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01209-2017","article-title":"Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years","volume":"50","author":"Raghu","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.drudis.2025.104450_b0090","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148554","article-title":"Therapeutic targets for cardiac fibrosis: from old school to next-gen","volume":"132","author":"Travers","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2025.104450_b0095","doi-asserted-by":"crossref","DOI":"10.1093\/burnst\/tkz003","article-title":"Strategies to prevent hypertrophic scar formation: a review of therapeutic interventions based on molecular evidence","volume":"8","author":"Shirakami","year":"2020","journal-title":"Burns Trauma"},{"key":"10.1016\/j.drudis.2025.104450_b0100","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s41030-023-00216-0","article-title":"Early diagnosis and treatment of idiopathic pulmonary fibrosis: a narrative review","volume":"9","author":"Alsomali","year":"2023","journal-title":"Pulm Ther"},{"key":"10.1016\/j.drudis.2025.104450_b0105","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/hep.32163","article-title":"Population screening for liver fibrosis: toward early diagnosis and intervention for chronic liver diseases","volume":"75","author":"Gin\u00e8s","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2025.104450_b0110","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201910865","article-title":"Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?","volume":"12","author":"Sweeney","year":"2020","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.drudis.2025.104450_b0115","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1464-410X.1992.tb15836.x","article-title":"The treatment of Peyronie\u2019s disease with tamoxifen","volume":"70","author":"Ralph","year":"1992","journal-title":"Br J Urol"},{"key":"10.1016\/j.drudis.2025.104450_b0120","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jsxm.2022.08.158","article-title":"Can tamoxifen and a PDE5 inhibitor slow the progression of Peyronie\u2019s disease?","volume":"19","author":"Megson","year":"2022","journal-title":"J Sex Med"},{"key":"10.1016\/j.drudis.2025.104450_b0125","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/jsxmed\/qdad083","article-title":"A combination of phosphodiesterase type 5 inhibitor and tamoxifen for acute Peyronie\u2019s disease: the first clinical signals","volume":"20","author":"Cellek","year":"2023","journal-title":"J Sex Med"},{"key":"10.1016\/j.drudis.2025.104450_b0130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13629-023-00416-y","article-title":"Treatment of acute phase of Peyronie\u2019s disease with tamoxifen and vardenafil\/tadalafil off label","volume":"14","author":"Jeannette","year":"2024","journal-title":"Tijdschr Urol"},{"key":"10.1016\/j.drudis.2025.104450_b0135","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/S0022-5347(05)68087-1","article-title":"Tamoxifen versus placebo in the treatment of Peyronie\u2019s disease","volume":"162","author":"Teloken","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.drudis.2025.104450_b0140","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/hep.24376","article-title":"Endpoints and clinical trial design for nonalcoholic steatohepatitis","volume":"54","author":"Sanyal","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2025.104450_b0145","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.14336\/AD.2020.0604","article-title":"Roles of biomarkers in myocardial fibrosis","volume":"11","author":"Ding","year":"2020","journal-title":"Aging Dis"},{"key":"10.1016\/j.drudis.2025.104450_b0150","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/359693a0","article-title":"Targeted disruption of the mouse transforming growth factor-\u03b21 gene results in multifocal inflammatory disease","volume":"359","author":"Shull","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2025.104450_b0155","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0092-8674(93)90228-I","article-title":"TGF\u03b1 deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice","volume":"73","author":"Luetteke","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2025.104450_b0160","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0092-8674(93)90227-H","article-title":"Mice with a null mutation of the TGF\u03b1 gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation","volume":"73","author":"Mann","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2025.104450_b0165","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1101\/gad.10.2.165","article-title":"Keratinocyte growth factor is required for hair development but not for wound healing","volume":"10","author":"Guo","year":"1996","journal-title":"Genes Dev"},{"key":"10.1016\/j.drudis.2025.104450_b0170","doi-asserted-by":"crossref","first-page":"7696","DOI":"10.1073\/pnas.84.21.7696","article-title":"Role of platelet-derived growth factor in wound healing: synergistic effects with other growth factors","volume":"84","author":"Lynch","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2025.104450_b0175","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1172\/JCI114210","article-title":"Growth factors in wound healing. Single and synergistic effects on partial thickness porcine skin wounds","volume":"84","author":"Lynch","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2025.104450_b0180","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1902\/jop.1991.62.11.710","article-title":"Effects of the platelet\u2010derived growth factor\/insulin\u2010like growth factor\u2010I combination on bone regeneration around titanium dental implants. Results of a pilot study in Beagle dogs","volume":"62","author":"Lynch","year":"1991","journal-title":"J Periodontol"},{"key":"10.1016\/j.drudis.2025.104450_b0185","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.1091\/mbc.e04-08-0759","article-title":"Coregulation of fibronectin signaling and matrix contraction by tenascin-C and syndecan-4","volume":"15","author":"Midwood","year":"2004","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.drudis.2025.104450_b0190","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1172\/JCI94753","article-title":"Fibroblast-specific TGF-\u03b2\u2013Smad2\/3 signaling underlies cardiac fibrosis","volume":"127","author":"Khalil","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2025.104450_b0195","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw8412","article-title":"Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials","volume":"11","author":"Lin","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2025.104450_b0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005135","article-title":"Large-scale off-target identification using fast and accurate dual regularized one-class collaborative filtering and its application to drug repurposing","volume":"12","author":"Lim","year":"2016","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.drudis.2025.104450_b0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000151","article-title":"Off-target effects of psychoactive drugs revealed by genome-wide assays in yeast","volume":"4","author":"Ericson","year":"2008","journal-title":"PLoS Genet"},{"key":"10.1016\/j.drudis.2025.104450_b0210","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.chembiol.2021.02.015","article-title":"High-content phenotypic and pathway profiling to advance drug discovery in diseases of unmet need","volume":"28","author":"Hughes","year":"2021","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2025.104450_b0215","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrd4592","article-title":"Dissecting fibrosis: therapeutic insights from the small-molecule toolbox","volume":"14","author":"Nanthakumar","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2025.104450_b0220","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/clpt.2012.236","article-title":"Phenotypic vs. target-based drug discovery for first-in-class medicines","volume":"93","author":"Swinney","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2025.104450_b0225","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/nrd1010","article-title":"A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole","volume":"2","author":"Olbe","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2025.104450_b0230","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1021\/jm00158a001","article-title":"The mechanism of action of the antisecretory agent omeprazole","volume":"29","author":"Lindberg","year":"1986","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104450_b0235","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.bjp.0707373","article-title":"Origin and evolution of high throughput screening","volume":"152","author":"Pereira","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drudis.2025.104450_b0240","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2025.104450_b0245","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrd4336","article-title":"The discovery of first-in-class drugs: origins and evolution","volume":"13","author":"Eder","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2025.104450_b0250","doi-asserted-by":"crossref","first-page":"12651","DOI":"10.1021\/acs.jmedchem.2c01737","article-title":"Is target-based drug discovery efficient? Discovery and \u201coff-target\u201d mechanisms of all drugs","volume":"66","author":"Sadri","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104450_b0255","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrd.2017.111","article-title":"Opportunities and challenges in phenotypic drug discovery: an industry perspective","volume":"16","author":"Moffat","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2025.104450_b0260","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.chembiol.2020.08.009","article-title":"Hit triage and validation in phenotypic screening: considerations and strategies","volume":"27","author":"Vincent","year":"2020","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2025.104450_b0265","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aab1201","article-title":"Developing predictive assays: the phenotypic screening \u201crule of 3.","volume":"7","author":"Vincent","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2025.104450_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.slasd.2024.02.001","article-title":"Perspectives on phenotypic screening\u2212screen design and assay technology special interest group","volume":"29","author":"Pak","year":"2024","journal-title":"SLAS Discov"},{"key":"10.1016\/j.drudis.2025.104450_b0275","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1021\/jm501562a","article-title":"Nintedanib: from discovery to the clinic","volume":"58","author":"Roth","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104450_b0280","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104450_b0285","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104450_b0290","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis\u2013associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104450_b0295","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104450_b0300","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2025.104450_b0305","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1183\/09059180.00001111","article-title":"Antifibrotic activities of pirfenidone in animal models","volume":"20","author":"Schaefer","year":"2011","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.drudis.2025.104450_b0310","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1021\/jm4019299","volume":"57","author":"Kelly","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104450_b0315","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104450_b0320","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/00185787241278571","article-title":"Resmetirom","volume":"60","author":"Levien","year":"2025","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.drudis.2025.104450_b0325","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41573-025-01158-9","article-title":"Fibrosis: cross-organ biology and pathways to development of innovative drugs","volume":"24","author":"Rieder","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2025.104450_b0330","doi-asserted-by":"crossref","first-page":"10002","DOI":"10.70322\/fibrosis.2025.10002","article-title":"Perspectives of drug therapy for non-alcoholic steatohepatitis-related liver fibrosis","volume":"3","author":"Victorovich","year":"2025","journal-title":"Fibrosis"},{"key":"10.1016\/j.drudis.2025.104450_b0335","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.3390\/biomedicines10092178","article-title":"Novel therapies for the treatment of cardiac fibrosis following myocardial infarction","volume":"10","author":"Raziyeva","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.drudis.2025.104450_b0340","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1053\/j.ajkd.2021.11.010","article-title":"Antifibrotic agents for the management of CKD: a review","volume":"80","author":"Ruiz-Ortega","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.drudis.2025.104450_b0345","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.874408","article-title":"New drugs for hepatic fibrosis","volume":"13","author":"Shan","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2025.104450_b0350","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3350\/cmh.2020.0187","article-title":"Anti-fibrotic treatments for chronic liver diseases: the present and the future","volume":"27","author":"Odagiri","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.drudis.2025.104450_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116282","article-title":"Comprehensive review of potential drugs with anti-pulmonary fibrosis properties","volume":"173","author":"Ma","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.drudis.2025.104450_b0360","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/endrev\/bnac018","article-title":"Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease","volume":"44","author":"Yabut","year":"2023","journal-title":"Endocr Rev"},{"key":"10.1016\/j.drudis.2025.104450_b0365","unstructured":"Akero Therapeutics Inc. A study evaluating efruxifermin in subjects with non-cirrhotic nonalcoholic steatohepatitis (NASH)\/metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. https:\/\/clinicaltrials.gov\/study\/NCT06215716; 2025."},{"key":"10.1016\/j.drudis.2025.104450_b0370","unstructured":"89bio Inc. A study evaluating the efficacy and safety of pegozafermin in participants with MASH and fibrosis (ENLIGHTEN-fibrosis). https:\/\/clinicaltrials.gov\/study\/NCT06318169; 2025."},{"key":"10.1016\/j.drudis.2025.104450_b0375","unstructured":"Beijing Continent Pharmaceutical Co Ltd. Hydronidone capsules in long-term treatment in patients with chronic viral hepatitis B liver fibrosis. https:\/\/clinicaltrials.gov\/study\/NCT05905172; 2025."},{"key":"10.1016\/j.drudis.2025.104450_b0380","unstructured":"Inventiva Pharma. A phase 3 study evaluating efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with (NASH) and fibrosis stages F2 and F3 (NATiV3) (NATiV3). https:\/\/clinicaltrials.gov\/study\/NCT04849728; 2024."},{"key":"10.1016\/j.drudis.2025.104450_b0385","unstructured":"Zydus Lifesciences Limited. A study to evaluate the safety and effectiveness of Saroglitazar 4 mg in patients with NAFLD with comorbidities. https:\/\/clinicaltrials.gov\/study\/NCT05872269; 2024."},{"key":"10.1016\/j.drudis.2025.104450_b0390","unstructured":"University of California SD. Semaglutide treatment in the real-world for fibrosis due to NAFLD in obesity and T2DM (SAMARA). https:\/\/clinicaltrials.gov\/study\/NCT06005012; 2023."},{"key":"10.1016\/j.drudis.2025.104450_b0395","unstructured":"Guangzhou JOYO Pharma Co., Ltd. SC1011 twice daily vs placebo in patients diagnosed with idiopathic pulmonary fibrosis (IPF). https:\/\/clinicaltrials.gov\/study\/NCT06125327; 2024."},{"key":"10.1016\/j.drudis.2025.104450_b0400","unstructured":"Boehringer Ingelheim. A follow-up study to test long-term treatment with nerandomilast in people with pulmonary fibrosis who took part in a previous study with nerandomilast (FIBRONEERTM-ON). https:\/\/clinicaltrials.gov\/study\/NCT06238622; 2025."},{"key":"10.1016\/j.drudis.2025.104450_b0405","unstructured":"Bristol-Myers Squibb. A study to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with progressive pulmonary fibrosis. https:\/\/clinicaltrials.gov\/study\/NCT06025578; 2025."},{"key":"10.1016\/j.drudis.2025.104450_b0410","unstructured":"Bristol-Myers Squibb. A study to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with idiopathic pulmonary fibrosis. https:\/\/clinicaltrials.gov\/study\/NCT06003426; 2025."},{"key":"10.1016\/j.drudis.2025.104450_b0415","unstructured":"United Therapeutics. Study of the efficacy and safety of Inhaled treprostinil in subjects with progressive pulmonary fibrosis (TETON-PPF). https:\/\/clinicaltrials.gov\/study\/NCT05943535; 2025."},{"key":"10.1016\/j.drudis.2025.104450_b0420","unstructured":"Boehringer Ingelheim. LIVERAGE\u2122: a study to test whether survodutide helps people with a liver disease called NASH\/MASH who have moderate or advanced liver fibrosis. https:\/\/clinicaltrials.gov\/study\/NCT06632444; 2025."},{"key":"10.1016\/j.drudis.2025.104450_b0425","unstructured":"Boehringer Ingelheim. LIVERAGE\u2122 \u2013 cirrhosis: a study to test whether survodutide helps people with a liver disease called NASH\/MASH who have cirrhosis. https:\/\/clinicaltrials.gov\/study\/NCT06632457; 2025."},{"key":"10.1016\/j.drudis.2025.104450_b0430","unstructured":"Boehringer Ingelheim. A study to test whether BI 1819479 improves lung function in people with idiopathic pulmonary fibrosis (IPF). https:\/\/clinicaltrials.gov\/study\/NCT06335303; 2025."},{"key":"10.1016\/j.drudis.2025.104450_b0435","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2205416","article-title":"Fazirsiran for liver disease associated with Alpha1-antitrypsin deficiency","volume":"387","author":"Strnad","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104450_b0440","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.cgh.2023.08.015","article-title":"Real-world efficacy of dupilumab in severe, treatment-refractory, and fibrostenotic patients with eosinophilic esophagitis","volume":"22","author":"Lee","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2025.104450_b0445","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1177\/1087057113495296","article-title":"Development of high-content assays for kidney progenitor cell expansion in transgenic zebrafish","volume":"18","author":"Sanker","year":"2013","journal-title":"SLAS Discov"},{"key":"10.1016\/j.drudis.2025.104450_b0450","doi-asserted-by":"crossref","first-page":"F631","DOI":"10.1152\/ajprenal.00379.2006","article-title":"In vitro models of TGF-\u03b2-induced fibrosis suitable for high-throughput screening of antifibrotic agents","volume":"293","author":"Xu","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.drudis.2025.104450_b0455","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1093\/ndt\/gfp245","article-title":"In vitro anti-fibrotic activities of herbal compounds and herbs","volume":"24","author":"Hu","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.drudis.2025.104450_b0460","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/rej.2011.1203","article-title":"Phenolic secoiridoids in extra virgin olive oil impede fibrogenic and oncogenic epithelial-to-mesenchymal transition: extra virgin olive oil as a source of novel antiaging phytochemicals","volume":"15","author":"Vazquez-Martin","year":"2012","journal-title":"Rejuvenation Res"},{"key":"10.1016\/j.drudis.2025.104450_b0465","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.yjmcc.2011.07.010","article-title":"A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes","volume":"52","author":"Jentzsch","year":"2012","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.drudis.2025.104450_b0470","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1165\/rcmb.2013-0099OC","article-title":"Inhibition of epithelial-to-mesenchymal transition and pulmonary fibrosis by methacycline","volume":"50","author":"Xi","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.drudis.2025.104450_b0475","doi-asserted-by":"crossref","first-page":"F705","DOI":"10.1152\/ajprenal.00503.2015","article-title":"Delayed treatment with PTBA analogs reduces postinjury renal fibrosis after kidney injury","volume":"310","author":"Skrypnyk","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.drudis.2025.104450_b0480","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.yjmcc.2016.04.015","article-title":"Discovery of novel small molecule inhibitors of cardiac hypertrophy using high throughput, high content imaging","volume":"97","author":"Reid","year":"2016","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.drudis.2025.104450_b0485","doi-asserted-by":"crossref","first-page":"L926","DOI":"10.1152\/ajplung.00121.2016","article-title":"Focal adhesion kinase signaling determines the fate of lung epithelial cells in response to TGF-\u03b2","volume":"312","author":"Ding","year":"2017","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.drudis.2025.104450_b0490","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/labinvest.2017.52","article-title":"Phenotypic screening identifies Axl kinase as a negative regulator of an alveolar epithelial cell phenotype","volume":"97","author":"Fujino","year":"2017","journal-title":"Lab Invest"},{"key":"10.1016\/j.drudis.2025.104450_b0495","doi-asserted-by":"crossref","first-page":"44867","DOI":"10.1038\/srep44867","article-title":"Tricyclic antidepressants promote ceramide accumulation to regulate collagen production in human hepatic stellate cells","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104450_b0500","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1021\/acschembio.7b00420","article-title":"Ex vivo cell-based screening platform for modulators of hepatosteatosis","volume":"12","author":"Yu","year":"2017","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.drudis.2025.104450_b0505","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1172\/JCI94624","article-title":"Fibroblast-specific inhibition of TGF-\u03b21 signaling attenuates lung and tumor fibrosis","volume":"127","author":"Wei","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2025.104450_b0510","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.209932","article-title":"RNAi screening identifies a mechanosensitive ROCK-JAK2-STAT3 network central to myofibroblast activation","volume":"131","author":"Oh","year":"2018","journal-title":"J Cell Sci"},{"key":"10.1016\/j.drudis.2025.104450_b0515","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207872","article-title":"Novel high\u2013throughput myofibroblast assays identify agonists with therapeutic potential in pulmonary fibrosis that act via EP2 and EP4 receptors","volume":"13","author":"Sieber","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104450_b0520","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/2211-5463.12552","article-title":"Identification of radiation\u2010induced EndMT inhibitors through cell\u2010based phenomic screening","volume":"9","author":"Song","year":"2019","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.drudis.2025.104450_b0525","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1021\/acs.jmedchem.8b01772","article-title":"5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic acids: a highly potent new class of inhibitors of Rho\/myocardin-related transcription factor (MRTF)\/serum response factor (SRF)-mediated gene transcription as potential antifibrotic agents for scleroderma","volume":"62","author":"Kahl","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104450_b0530","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277646","article-title":"Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie\u2019s disease","volume":"17","author":"Ilg","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104450_b0535","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.eururo.2018.10.014","article-title":"Antifibrotic synergy between phosphodiesterase type 5 inhibitors and selective oestrogen receptor modulators in Peyronie\u2019s disease models","volume":"75","author":"Ilg","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.drudis.2025.104450_b0540","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1021\/acschembio.8b00260","article-title":"Small molecule and pooled CRISPR screens investigating IL17 signaling identify BRD2 as a novel contributor to keratinocyte inflammatory responses","volume":"14","author":"Slivka","year":"2019","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.drudis.2025.104450_b0545","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1038\/s41598-019-41491-9","article-title":"Functional screening identifies microRNAs as multi-cellular regulators of heart failure","volume":"9","author":"Verjans","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104450_b0550","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123987","article-title":"High-throughput screening discovers antifibrotic properties of haloperidol by hindering myofibroblast activation","volume":"4","author":"Rehman","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.drudis.2025.104450_b0555","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41420-019-0226-y","article-title":"Idebenone has preventative and therapeutic effects on pulmonary fibrosis via preferential suppression of fibroblast activity","volume":"5","author":"Sugizaki","year":"2019","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.drudis.2025.104450_b0560","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1016\/j.celrep.2019.11.019","article-title":"Modeling progressive fibrosis with pluripotent stem cells identifies an anti-fibrotic small molecule","volume":"29","author":"Vijayaraj","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2025.104450_b0565","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s42490-019-0014-z","article-title":"A high content, phenotypic \u2018scar-in-a-jar\u2019 assay for rapid quantification of collagen fibrillogenesis using disease-derived pulmonary fibroblasts","volume":"1","author":"Good","year":"2019","journal-title":"BMC Biomed Eng"},{"key":"10.1016\/j.drudis.2025.104450_b0570","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3390\/cells9040964","article-title":"Human liver spheroids as a model to study aetiology and treatment of hepatic fibrosis","volume":"9","author":"Hurrell","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2025.104450_b0575","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.yjmcc.2020.04.002","article-title":"A high-content, in vitro cardiac fibrosis assay for high-throughput, phenotypic identification of compounds with anti-fibrotic activity","volume":"142","author":"Palano","year":"2020","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.drudis.2025.104450_b0580","article-title":"Molecular profiling reveals a common metabolic signature of tissue fibrosis","volume":"1","author":"Zhang","year":"2020","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.drudis.2025.104450_b0585","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.582602","article-title":"Kinetic analysis of label-free microscale collagen gel contraction using machine learning-aided image analysis","volume":"8","author":"Yamanishi","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.drudis.2025.104450_b0590","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1165\/rcmb.2019-0296OC","article-title":"Screening for YAP inhibitors identifies statins as modulators of fibrosis","volume":"62","author":"Santos","year":"2020","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.drudis.2025.104450_b0595","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1165\/rcmb.2021-0428OC","article-title":"Screening for inhibitors of YAP nuclear localization identifies Aurora kinase A as a modulator of lung fibrosis","volume":"67","author":"Yang","year":"2022","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.drudis.2025.104450_b0600","doi-asserted-by":"crossref","DOI":"10.1063\/5.0054967","article-title":"A scalable 3D tissue culture pipeline to enable functional therapeutic screening for pulmonary fibrosis","volume":"5","author":"Cummins","year":"2021","journal-title":"APL Bioeng"},{"key":"10.1016\/j.drudis.2025.104450_b0605","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1016\/j.stemcr.2021.10.015","article-title":"Disease modeling of pulmonary fibrosis using human pluripotent stem cell-derived alveolar organoids","volume":"16","author":"Suezawa","year":"2021","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.drudis.2025.104450_b0610","doi-asserted-by":"crossref","first-page":"10931","DOI":"10.1038\/s41598-021-90263-x","article-title":"Identification of hepatic fibrosis inhibitors through morphometry analysis of a hepatic multicellular spheroids model","volume":"11","author":"Song","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104450_b0615","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/24725552211019405","article-title":"Application of a high-content screening assay utilizing primary human lung fibroblasts to identify antifibrotic drugs for rapid repurposing in COVID-19 patients","volume":"26","author":"Marwick","year":"2021","journal-title":"SLAS Discov"},{"key":"10.1016\/j.drudis.2025.104450_b0620","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.2147\/JIR.S304828","article-title":"Exogenous plant gma-miR-159a, identified by miRNA library functional screening, ameliorated hepatic stellate cell activation and inflammation via inhibiting GSK-3\u03b2-mediated pathways","volume":"14","author":"Yu","year":"2021","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.drudis.2025.104450_b0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108339","article-title":"1\u03b2-Hydroxyalantolactone from Inulae Flos alleviated the progression of pulmonary fibrosis via inhibiting JNK\/FOXO1\/NF-\u03baB pathway","volume":"101","author":"Yu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.drudis.2025.104450_b0630","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb3673","article-title":"Phenotypic drug screening in a human fibrosis model identified a novel class of antifibrotic therapeutics","volume":"7","author":"Gerckens","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2025.104450_b0635","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2115960119","article-title":"Agonists of prostaglandin E2 receptors as potential first in class treatment for nephronophthisis and related ciliopathies","volume":"119","author":"Garcia","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2025.104450_b0640","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1021\/acschembio.2c00006","article-title":"Genome-wide CRISPR screening to identify drivers of TGF-\u03b2-induced liver fibrosis in human hepatic stellate cells","volume":"17","author":"Yu","year":"2022","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.drudis.2025.104450_b0645","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s13287-022-02987-w","article-title":"Anti-fibrotic effect of a selective estrogen receptor modulator in systemic sclerosis","volume":"13","author":"Kim","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.drudis.2025.104450_b0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175374","article-title":"Phenotypic screening identifies hydroxypyridone anti-fungals as novel medicines for the prevention of hypertrophic scars","volume":"937","author":"Lapthorn","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2025.104450_b0655","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/intbio\/zyac001","article-title":"Contracting scars from fibrin drops","volume":"14","author":"Robinson","year":"2022","journal-title":"Integr Biol (Camb)"},{"key":"10.1016\/j.drudis.2025.104450_b0660","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jare.2022.05.008","article-title":"Human corneal stromal stem cells express anti-fibrotic microRNA-29a and 381-5p \u2013 a robust cell selection tool for stem cell therapy of corneal scarring","volume":"45","author":"Yam","year":"2023","journal-title":"J Adv Res"},{"key":"10.1016\/j.drudis.2025.104450_b0665","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/CIRCRESAHA.122.321475","article-title":"Inhibition of eicosanoid degradation mitigates fibrosis of the heart","volume":"132","author":"Rubino","year":"2023","journal-title":"Circ Res"},{"key":"10.1016\/j.drudis.2025.104450_b0670","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13619-022-00148-1","article-title":"Modeling drug-induced liver injury and screening for anti-hepatofibrotic compounds using human PSC-derived organoids","volume":"12","author":"Wu","year":"2023","journal-title":"Cell Regener"},{"key":"10.1016\/j.drudis.2025.104450_b0675","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.chembiol.2023.06.014","article-title":"Integrating inflammatory biomarker analysis and artificial-intelligence-enabled image-based profiling to identify drug targets for intestinal fibrosis","volume":"30","author":"Yu","year":"2023","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2025.104450_b0680","doi-asserted-by":"crossref","first-page":"15104","DOI":"10.3390\/ijms242015104","article-title":"A methodological approach to identify natural compounds with antifibrotic activity and the potential to treat pulmonary fibrosis using single-cell sequencing and primary human lung macrophages","volume":"24","author":"Apte","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104450_b0685","article-title":"An in vivo screening platform identifies senolytic compounds that target p16INK4a+ fibroblasts in lung fibrosis","volume":"134","author":"Lee","year":"2024","journal-title":"J Clinl Invest"},{"key":"10.1016\/j.drudis.2025.104450_b0690","doi-asserted-by":"crossref","first-page":"7143","DOI":"10.1016\/j.cell.2024.09.034","article-title":"Multiscale drug screening for cardiac fibrosis identifies MD2 as a therapeutic target","volume":"187","author":"Zhang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2025.104450_b0695","doi-asserted-by":"crossref","DOI":"10.1088\/1758-5090\/ad998c","article-title":"Development of immunocompetent full thickness skin tissue constructs to model skin fibrosis for high-throughput drug screening","volume":"17","author":"Lim","year":"2025","journal-title":"Biofabrication"},{"key":"10.1016\/j.drudis.2025.104450_b0700","article-title":"Enhancing throughput and robustness of the fibroblast to myofibroblast transition assay","volume":"32","author":"B\u00e4ck","year":"2025","journal-title":"SLAS Disco"},{"key":"10.1016\/j.drudis.2025.104450_b0705","article-title":"Chemogenomic screening in a patient\u2010derived 3D fatty liver disease model reveals the CHRM1\u2010TRPM8 axis as a novel module for targeted intervention","volume":"12","author":"Youhanna","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.drudis.2025.104450_b0710","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1167\/iovs.07-1610","article-title":"Lovastatin inhibits TGF-\u03b2\u2013induced myofibroblast transdifferentiation in human Tenon fibroblasts","volume":"49","author":"Meyer-ter-Vehn","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2025.104450_b0715","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.607968","article-title":"Simvastatin and ROCK inhibitor Y-27632 inhibit myofibroblast differentiation of Graves\u2019 ophthalmopathy-derived orbital fibroblasts via RhoA-mediated ERK and p38 signaling pathways","volume":"11","author":"Wei","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.drudis.2025.104450_b0720","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/jsxmed\/qdad051","article-title":"Statins synergize with phosphodiesterase type 5 inhibitors but not with selective estrogen receptor modulators to prevent myofibroblast transformation in an in vitro model of Peyronie\u2019s disease","volume":"20","author":"Ilg","year":"2023","journal-title":"J Sex Med"},{"key":"10.1016\/j.drudis.2025.104450_b0725","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1165\/rcmb.2004-0127OC","article-title":"Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts","volume":"32","author":"Watts","year":"2005","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.drudis.2025.104450_b0730","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23074","article-title":"Atorvastatin attenuates pulmonary fibrosis in mice and human lung fibroblasts, by the regulation of myofibroblast differentiation and apoptosis","volume":"36","author":"Yildirim","year":"2022","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1016\/j.drudis.2025.104450_b0735","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000094780","article-title":"Inhibitory effect of statins on renal epithelial-to-mesenchymal transition","volume":"26","author":"Patel","year":"2006","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.drudis.2025.104450_b0740","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1002\/art.23677","article-title":"Rho\u2010associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts","volume":"58","author":"Akhmetshina","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.drudis.2025.104450_b0745","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/apha.12085","article-title":"Effects of simvastatin on pulmonary fibrosis, pulmonary hypertension and exercise capacity in bleomycin\u2010treated rats","volume":"208","author":"Schroll","year":"2013","journal-title":"Acta Physiol"},{"key":"10.1016\/j.drudis.2025.104450_b0750","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3389\/fphar.2017.00473","article-title":"Lovastatin alleviates endothelial-to-mesenchymal transition in glomeruli via suppression of oxidative stress and TGF-\u03b21 signaling","volume":"8","author":"Ma","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2025.104450_b0755","doi-asserted-by":"crossref","first-page":"38034","DOI":"10.1038\/srep38034","article-title":"Greater efficacy of atorvastatin versus a non-statin lipid-lowering agent against renal injury: potential role as a histone deacetylase inhibitor","volume":"6","author":"Singh","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104450_b0760","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1046\/j.1523-1755.2001.00724.x","article-title":"Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction","volume":"59","author":"Moriyama","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.drudis.2025.104450_b0765","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/ndt\/gfh859","article-title":"Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction","volume":"20","author":"Mauro Vieira","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.drudis.2025.104450_b0770","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jhep.2010.04.025","article-title":"Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells","volume":"53","author":"Trebicka","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2025.104450_b0775","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/1440-1681.12446","article-title":"Antifibrotic effect of AT\u20101 blocker and statin in rats with hepatic fibrosis","volume":"42","author":"El-Ashmawy","year":"2015","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.drudis.2025.104450_b0780","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s12013-013-9698-1","article-title":"The therapeutic effects of bone marrow-derived mesenchymal stem cells and simvastatin in a rat model of liver fibrosis","volume":"68","author":"Motawi","year":"2014","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.drudis.2025.104450_b0785","doi-asserted-by":"crossref","first-page":"G126","DOI":"10.1152\/ajpgi.00299.2009","article-title":"Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis","volume":"298","author":"Yang","year":"2010","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.drudis.2025.104450_b0790","first-page":"238","article-title":"Rosuvastatin inhibits inflammatory response and resists fibrosis after myocardial infarction","volume":"22","author":"Bao","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.drudis.2025.104450_b0795","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014145","article-title":"Statins inhibit angiotensin II\/Smad pathway and related vascular fibrosis, by a TGF-\u03b2-independent process","volume":"5","author":"Rodrigues D\u00edez","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104450_b0800","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/hr.2010.243","article-title":"Protective effects of statin on cardiac fibrosis and apoptosis in adrenomedullin-knockout mice treated with angiotensin II and high salt loading","volume":"34","author":"Yamamoto","year":"2011","journal-title":"Hypertens Res"},{"key":"10.1016\/j.drudis.2025.104450_b0805","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3390\/jcm8060794","article-title":"Simvastatin attenuates cardiac fibrosis via regulation of cardiomyocyte-derived exosome secretion","volume":"8","author":"Kuo","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.drudis.2025.104450_b0810","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1161\/HYPERTENSIONAHA.115.07089","article-title":"SmgGDS as a crucial mediator of the inhibitory effects of statins on cardiac hypertrophy and fibrosis","volume":"67","author":"Kudo","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.drudis.2025.104450_b0815","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/rheumatology\/ket144","article-title":"Simvastatin attenuates the development of pulmonary and cutaneous fibrosis in a murine model of systemic sclerosis","volume":"52","author":"Bagnato","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.drudis.2025.104450_b0820","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tice.2015.01.003","article-title":"The possible protective effect of simvastatin and pioglitazone separately and in combination on bleomycin-induced changes in mice thin skin","volume":"47","author":"Kandeel","year":"2015","journal-title":"Tissue Cell"},{"key":"10.1016\/j.drudis.2025.104450_b0825","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179350","article-title":"Differential effects of Losartan and Atorvastatin in partial and full thickness burn wounds","volume":"12","author":"Akershoek","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104450_b0830","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/wrr.12811","article-title":"Liposome\u2010encapsulated statins reduce hypertrophic scarring through topical application","volume":"28","author":"Xie","year":"2020","journal-title":"Wound Repair Regen"},{"key":"10.1016\/j.drudis.2025.104450_b0835","doi-asserted-by":"crossref","first-page":"252e","DOI":"10.1097\/PRS.0b013e31823aea10","article-title":"HMG-CoA reductase inhibitors (statins) reduce hypertrophic scar formation in a rabbit ear wounding model","volume":"129","author":"Ko","year":"2012","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.drudis.2025.104450_b0840","doi-asserted-by":"crossref","first-page":"e1294","DOI":"10.1097\/GOX.0000000000001294","article-title":"Local application of statins significantly reduced hypertrophic scarring in a rabbit ear model","volume":"5","author":"Jia","year":"2017","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"10.1016\/j.drudis.2025.104450_b0845","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1164\/rccm.201108-1574OC","article-title":"Statins and pulmonary fibrosis","volume":"185","author":"Xu","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.drudis.2025.104450_b0850","doi-asserted-by":"crossref","first-page":"81588","DOI":"10.3389\/fphar.2022.815882","article-title":"Statin therapy for hyperlipidemic patients with chronic kidney disease and end-stage renal disease: a retrospective cohort study based on 925,418 adults in Taiwan","volume":"13","author":"Sung","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2025.104450_b0855","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1053\/j.ajkd.2016.01.016","article-title":"Effect of statins on kidney disease outcomes: a systematic review and meta-analysis","volume":"67","author":"Su","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.drudis.2025.104450_b0860","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115644","article-title":"Anti-fibrotic effects of statin drugs: a review of evidence and mechanisms","volume":"214","author":"Dolivo","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drudis.2025.104450_b0865","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","article-title":"Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"15","author":"Kim","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2025.104450_b0870","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/jim-2016-000092","article-title":"Effects of 12 Weeks of atorvastatin therapy on myocardial fibrosis and circulating fibrosis biomarkers in statin-na\u00efve patients with hypertension with atherosclerosis","volume":"64","author":"Chang","year":"2016","journal-title":"J Investig Med"},{"key":"10.1016\/j.drudis.2025.104450_b0875","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/wrr.12878","article-title":"Statin treatment and hypertrophic scarring after cardiac surgery","volume":"29","author":"Chello","year":"2021","journal-title":"Wound Repair Regen"},{"key":"10.1016\/j.drudis.2025.104450_b0880","doi-asserted-by":"crossref","first-page":"11737","DOI":"10.7150\/thno.47717","article-title":"Glycogen synthase kinase-3\u03b2: a promising candidate in the fight against fibrosis","volume":"10","author":"Zheng","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.drudis.2025.104450_b0885","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/1756-185X.13247","article-title":"Anti\u2010fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis\u2010associated interstitial lung disease","volume":"21","author":"Xiao","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.drudis.2025.104450_b0890","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.maturitas.2010.05.009","article-title":"SERMs: progress and future perspectives","volume":"67","author":"Pickar","year":"2010","journal-title":"Maturitas"},{"key":"10.1016\/j.drudis.2025.104450_b0895","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.jsxm.2020.06.022","article-title":"Phosphodiesterase type 5 inhibitors and selective estrogen receptor modulators can prevent but not reverse myofibroblast transformation in Peyronie\u2019s disease","volume":"17","author":"Ilg","year":"2020","journal-title":"J Sex Med"},{"key":"10.1016\/j.drudis.2025.104450_b0900","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/archfaci.8.5.329","article-title":"Effects of tamoxifen on normal human dermal fibroblasts","volume":"8","author":"Ruffy","year":"2006","journal-title":"Arch Facial Plast Surg"},{"key":"10.1016\/j.drudis.2025.104450_b0905","doi-asserted-by":"crossref","first-page":"F309","DOI":"10.1152\/ajprenal.2000.279.2.F309","article-title":"Selective estrogen receptor modulators suppress mesangial cell collagen synthesis","volume":"279","author":"Neugarten","year":"2000","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.drudis.2025.104450_b0910","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1093\/ndt\/gfu240","article-title":"Tamoxifen ameliorates renal tubulointerstitial fibrosis by modulation of estrogen receptor \u03b1-mediated transforming growth factor-\u03b21\/Smad signaling pathway","volume":"29","author":"Kim","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.drudis.2025.104450_b0915","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1681\/ASN.2011010046","article-title":"Antifibrotic effect of tamoxifen in a model of progressive renal disease","volume":"23","author":"Dell\u00ea","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.drudis.2025.104450_b0920","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ejim.2012.11.010","article-title":"Long-term safety and efficacy of a tamoxifen-based treatment strategy for idiopathic retroperitoneal fibrosis","volume":"24","author":"van Bommel","year":"2013","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.drudis.2025.104450_b0925","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/ndt\/gfq362","article-title":"Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study","volume":"26","author":"Korte","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.drudis.2025.104450_b0930","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1378\/chest.111.4.1137","article-title":"Successful treatment of sclerosing cervicitis and fibrosing mediastinitis with tamoxifen","volume":"111","author":"Savelli","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.drudis.2025.104450_b0935","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-022-01299-y","article-title":"Short-term tamoxifen administration improves hepatic steatosis and glucose intolerance through JNK\/MAPK in mice","volume":"8","author":"Fang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2025.104450_b0940","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1007\/s10620-015-3660-6","article-title":"Raloxifene ameliorates liver fibrosis of nonalcoholic steatohepatitis induced by choline-deficient high-fat diet in ovariectomized mice","volume":"60","author":"Luo","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.drudis.2025.104450_b0945","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2017.02.039","article-title":"Effects of raloxifene on portal hypertension and hepatic encephalopathy in cirrhotic rats","volume":"802","author":"Chang","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2025.104450_b0950","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/cas.12474","article-title":"A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer","volume":"105","author":"Lin","year":"2014","journal-title":"Cancer Sci"},{"key":"10.1016\/j.drudis.2025.104450_b0955","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/hep4.2008","article-title":"Tamoxifen use and potential effects on liver parenchyma: a long\u2010term prospective transient elastographic evaluation","volume":"6","author":"Braal","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.drudis.2025.104450_b0960","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jhep.2012.08.003","article-title":"Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial","volume":"57","author":"Furusyo","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2025.104450_b0965","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1165\/rcmb.2002-0243OC","article-title":"Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation","volume":"29","author":"Kolodsick","year":"2003","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.drudis.2025.104450_b0970","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1165\/rcmb.2012-0262OC","article-title":"Reversal of myofibroblast differentiation by prostaglandin E2","volume":"48","author":"Garrison","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.drudis.2025.104450_b0975","doi-asserted-by":"crossref","first-page":"L1257","DOI":"10.1152\/ajplung.2001.281.5.L1257","article-title":"Prostaglandin E2 inhibits fibroblast chemotaxis","volume":"281","author":"Kohyama","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.drudis.2025.104450_b0980","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1165\/rcmb.4857","article-title":"Prostaglandin E2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2-dependent","volume":"27","author":"Lama","year":"2002","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.drudis.2025.104450_b0985","doi-asserted-by":"crossref","first-page":"L405","DOI":"10.1152\/ajplung.00232.2006","article-title":"Prostaglandin E2 inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling","volume":"292","author":"Huang","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.drudis.2025.104450_b0990","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13291","article-title":"Activation of the prostaglandin E2 EP2 receptor attenuates renal fibrosis in unilateral ureteral obstructed mice and human kidney slices","volume":"227","author":"Jensen","year":"2019","journal-title":"Acta Physiol"},{"key":"10.1016\/j.drudis.2025.104450_b0995","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/ki.2012.115","article-title":"The intrinsic prostaglandin E2\u2013EP4 system of the renal tubular epithelium limits the development of tubulointerstitial fibrosis in mice","volume":"82","author":"Nakagawa","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.drudis.2025.104450_b1000","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13318","article-title":"Translating kidney fibrosis: role of the EP2 receptor","volume":"227","author":"Sands","year":"2019","journal-title":"Acta Physiol"},{"key":"10.1016\/j.drudis.2025.104450_b1005","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jaci.2019.11.032","article-title":"Inhibiting eicosanoid degradation exerts antifibrotic effects in a pulmonary fibrosis mouse model and human tissue","volume":"145","author":"B\u00e4rnthaler","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2025.104450_b1010","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejpb.2012.11.023","article-title":"Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2","volume":"84","author":"Ivanova","year":"2013","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.drudis.2025.104450_b1015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1465-9921-11-34","article-title":"A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice","volume":"11","author":"Zhu","year":"2010","journal-title":"Respir Res"},{"key":"10.1016\/j.drudis.2025.104450_b1020","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.plefa.2011.01.003","article-title":"Prostaglandin E2 increases cardiac fibroblast proliferation and increases cyclin D expression via EP1 receptor","volume":"84","author":"Harding","year":"2011","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.drudis.2025.104450_b1025","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3892\/ijmm.2014.1979","article-title":"Prostaglandin E2 EP1 receptor enhances TGF-\u03b21-induced mesangial cell injury","volume":"35","author":"Chen","year":"2015","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.drudis.2025.104450_b1030","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3390\/cells8060619","article-title":"Therapeutic potential of hematopoietic prostaglandin D2 synthase in allergic inflammation","volume":"8","author":"Rittchen","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2025.104450_b1035","doi-asserted-by":"crossref","first-page":"e2254","DOI":"10.1096\/fj.202201867R","article-title":"Artesunate protects against ocular fibrosis by suppressing fibroblast activation and inducing mitochondria\u2010dependent ferroptosis","volume":"37","author":"Liu","year":"2023","journal-title":"FASEB J"},{"key":"10.1016\/j.drudis.2025.104450_b1040","doi-asserted-by":"crossref","first-page":"16358","DOI":"10.1021\/acsomega.4c00020","article-title":"Artesunate alleviates kidney fibrosis in type 1 diabetes with periodontitis rats via promoting autophagy and suppression of inflammation","volume":"9","author":"Liang","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.drudis.2025.104450_b1045","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3892\/etm.2017.4573","article-title":"Artesunate ameliorates lung fibrosis via inhibiting the Notch signaling pathway","volume":"14","author":"Liu","year":"2017","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.drudis.2025.104450_b1050","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.2018.32.1_supplement.660.7","article-title":"Artesunate antagonizes myofibroblast markers and fibrosis\u2010associated extracellular matrix protein expression in human dermal fibroblasts","volume":"32","author":"Larson","year":"2018","journal-title":"FASEB J"},{"key":"10.1016\/j.drudis.2025.104450_b1055","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40360-018-0255-9","article-title":"Artesunate may inhibit liver fibrosis via the FAK\/Akt\/\u03b2-catenin pathway in LX-2 cells","volume":"19","author":"Lv","year":"2018","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.drudis.2025.104450_b1060","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.biopha.2018.11.030","article-title":"Artesunate alleviates liver fibrosis by regulating ferroptosis signaling pathway","volume":"109","author":"Kong","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.drudis.2025.104450_b1065","unstructured":"Stanford University. Open-label dose-escalation treatment study of patients with IPF (DIAMOND). https:\/\/clinicaltrials.gov\/study\/NCT05988463."},{"key":"10.1016\/j.drudis.2025.104450_b1070","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/art.22314","article-title":"Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis","volume":"56","author":"Distler","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.drudis.2025.104450_b1075","doi-asserted-by":"crossref","first-page":"F142","DOI":"10.1152\/ajprenal.00320.2009","article-title":"Noncanonical TGF-\u03b2 pathways, mTORC1 and Abl, in renal interstitial fibrogenesis","volume":"298","author":"Wang","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.drudis.2025.104450_b1080","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1748-717X-4-66","article-title":"Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model","volume":"4","author":"Li","year":"2009","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.drudis.2025.104450_b1085","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/art.24186","article-title":"Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis","volume":"60","author":"Akhmetshina","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.drudis.2025.104450_b1090","doi-asserted-by":"crossref","first-page":"G907","DOI":"10.1152\/ajpgi.00420.2004","article-title":"Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats","volume":"288","author":"Yoshiji","year":"2005","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.drudis.2025.104450_b1095","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1096\/fj.07-105627","article-title":"Dual inhibition of c\u2010Abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis","volume":"22","author":"Akhmetshina","year":"2008","journal-title":"FASEB J"},{"key":"10.1016\/j.drudis.2025.104450_b1100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11926-010-0146-6","article-title":"Imatinib and the treatment of fibrosis: recent trials and tribulations","volume":"13","author":"Gordon","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.drudis.2025.104450_b1105","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1074\/mcp.M800258-MCP200","article-title":"Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell type-specific functions","volume":"8","author":"Pan","year":"2009","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.drudis.2025.104450_b1110","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/ijc.2910620613","article-title":"Recurrent cytogenetic alterations of prostate carcinoma and amplification of c\u2010myc or epidermal growth factor receptor in subclones of immortalized PNT1 human prostate epithelial cell line","volume":"62","author":"Degeorges","year":"1995","journal-title":"Int J Cancer"},{"key":"10.1016\/j.drudis.2025.104450_b1115","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/btpr.2666","article-title":"Characterization of phenotypic and genotypic diversity in subclones derived from a clonal cell line","volume":"34","author":"Tharmalingam","year":"2018","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.drudis.2025.104450_b1120","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/(SICI)1097-4598(199805)21:5<599::AID-MUS6>3.0.CO;2-3","article-title":"Genotypic and phenotypic changes in exhaustively grown cell lines from mitochondrial cytopathy patients","volume":"21","author":"Siregar","year":"1998","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.drudis.2025.104450_b1125","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/cam4.219","article-title":"U\u2010251 revisited: genetic drift and phenotypic consequences of long\u2010term cultures of glioblastoma cells","volume":"3","author":"Torsvik","year":"2014","journal-title":"Cancer Med"},{"key":"10.1016\/j.drudis.2025.104450_b1130","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1074\/jbc.R113.529156","article-title":"Small molecule screening in human induced pluripotent stem cell-derived terminal cell types","volume":"289","author":"Engle","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2025.104450_b1135","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4252\/wjsc.v11.i1.33","article-title":"Current methods for the maturation of induced pluripotent stem cell-derived cardiomyocytes","volume":"11","author":"Machiraju","year":"2019","journal-title":"World J Stem Cells"},{"key":"10.1016\/j.drudis.2025.104450_b1140","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41392-024-01809-0","article-title":"Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications","volume":"9","author":"Cerneckis","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2025.104450_b1145","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022293","article-title":"TGF-\u03b21 signaling and tissue fibrosis","volume":"10","author":"Kim","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.drudis.2025.104450_b1150","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202303561","article-title":"Compound absorption in polymer devices impairs the translatability of preclinical safety assessments","volume":"13","author":"Kemas","year":"2024","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.drudis.2025.104450_b1155","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1039\/b612140c","article-title":"PDMS absorption of small molecules and consequences in microfluidic applications","volume":"6","author":"Toepke","year":"2006","journal-title":"Lab Chip"},{"key":"10.1016\/j.drudis.2025.104450_b1160","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.vascn.2009.12.005","article-title":"Reduction of non-specific adsorption of drugs to plastic containers used in bioassays or analyses","volume":"61","author":"Fukazawa","year":"2010","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.drudis.2025.104450_b1165","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"SLAS Discov"},{"key":"10.1016\/j.drudis.2025.104450_b1170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneumeth.2020.108699","article-title":"Adaptation of robust Z\u2019 factor for assay quality assessment in microelectrode array based screening using adult dorsal root ganglion neurons","volume":"339","author":"Atmaramani","year":"2020","journal-title":"J Neurosci Methods"},{"key":"10.1016\/j.drudis.2025.104450_b1175","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1038\/s41598-019-40660-0","article-title":"DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitro","volume":"9","author":"Verheijen","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104450_b1180","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1177\/24726303211056338","article-title":"Assay guidance manual for drug discovery: technologies that matter","volume":"26","author":"Markossian","year":"2021","journal-title":"SLAS Technol"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625001631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625001631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T23:39:09Z","timestamp":1757115549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625001631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":236,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1359644625001631"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104450","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel anti-fibrotics through phenotypic screening","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104450","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104450"}}